Treatment with recombinant mouse IL-22 via intraperitoneal (i.p.)injection after mouse allogeneic bone marrow transplantation enhanced the recovery of intestinal stem cells (ISCs), increased epithelial regeneration and reduced intestinal pathology and mortality from GVHD [19]. Here, IL22 is linked to graft versus host disease.